Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Navidea Biopharmaceuticals's enterprise value is $-2.60 Mil.
Navidea Biopharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was $-8.89 Mil. Therefore, Navidea Biopharmaceuticals's EV-to-EBITDA for today is 0.29.
The historical rank and industry rank for Navidea Biopharmaceuticals's EV-to-EBITDA or its related term are showing as below:
NAVBQ'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.29
Current: 0.29
During the past 13 years, the highest EV-to-EBITDA of Navidea Biopharmaceuticals was 0.29. The lowest was 0.00. And the median was 0.00.
NAVBQ's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 11.92
vs NAVBQ: 0.29
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Navidea Biopharmaceuticals's PE Ratio (TTM) for today is calculated as:
Navidea Biopharmaceuticals's share price for today is $0.0001.
Navidea Biopharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.060.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NAVBQ vs PKBO, RSPI, ATRX: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Navidea Biopharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Navidea Biopharmaceuticals EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Navidea Biopharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Navidea Biopharmaceuticals's EV-to-EBITDA falls into.
Navidea Biopharmaceuticals's current Enterprise Value is $-2.60 Mil.
Navidea Biopharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.89 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Navidea Biopharmaceuticals (NAVBQ) has a EV-to-EBITDA of 0.29 as of Aug. 04, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Navidea Biopharmaceuticals.
Is Navidea Biopharmaceuticals' EV-to-EBITDA too high?
Navidea Biopharmaceuticals' current EV-to-EBITDA is 0.29. The Biotechnology industry median EV-to-EBITDA is 11.92. Navidea Biopharmaceuticals' value of 0.29 is 97.6% below this industry median. Overall, Navidea Biopharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Navidea Biopharmaceuticals' EV-to-EBITDA compare to PKBO and RSPI?
Navidea Biopharmaceuticals' EV-to-EBITDA of 0.29 can be compared against companies in the Biotechnology industry. The industry median EV-to-EBITDA is 11.92. Navidea Biopharmaceuticals' value of 0.29 is 97.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 11.92, based on 415 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Navidea Biopharmaceuticals's current EV-to-EBITDA of 0.29 is 97.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Navidea Biopharmaceuticals. For the Biotechnology industry, the median EV-to-EBITDA is 11.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Navidea Biopharmaceuticals's current EV-to-EBITDA is 0.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Navidea Biopharmaceuticals stock overvalued right now?
Navidea Biopharmaceuticals (NAVBQ) has a current EV-to-EBITDA of 0.29. The current EV-to-EBITDA is 0.29 and 97.6% below the Biotechnology industry median of 11.92. Navidea Biopharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Navidea Biopharmaceuticals (NAVBQ), the current EV-to-EBITDA is 0.29 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Navidea Biopharmaceuticals Inc is a biotechnology company specializied in precision medicine. Its products, precision immunodiagnostic agents and immunotherapeutic products are designed to assist in the identification of undetected diseases and to improve targeted treatment. The company's platform, known as Manocept technology, aims to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. One of the company's products is Lymphoseek, a radioactive diagnostic agent indicated to locate lymph nodes.
16GF Score
Get the complete analysis for NAVBQ
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NAVBQ has been successfully added to your 
